Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
Summary
Zevra has the option to pay up to 25% of the interest on principal amounts outstanding in-kind through and including , subject to certain terms and conditions. By restructuring the amounts previously outstanding on two different facilities, we have simplified and extended the maturity while also providing additional non-dilutive capital flexibility to support our strategic priorities for 2024, which are (i) successfully launching OLPRUVA\xae and ensuring access for patients, (ii) preparing for the launch of arimoclomol, if approved, and (iii) advancing our KP1077 development program in sleep disorders. With multiple near-term catalysts, including a potential product approval later this year and upcoming development milestones, we are excited to support the Company and management team as they continue growing toward profitability.Founded in 1999, focuses on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.For more information, please visit www.zevra.com or follow us on X (formerly Twitter) and LinkedIn.This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change.